Compugen Ltd. reported its financial results for the first quarter of 2025, showing revenues of approximately $2.3 million, a decrease from the $2.6 million reported in the first quarter of 2024. The decline in revenue reflects differences in the recognition of portions of both the upfront payment and the IND milestone payment from a license agreement with Gilead. The company recorded a net loss of approximately $7.2 million, maintaining the same earnings per share of $0.08 as in 2024, despite the loss being slightly lower than the $7.3 million reported in the previous year. Research and development expenses for the first quarter of 2025 were approximately $5.8 million, compared to $6.4 million in the same period of 2024. General and administrative expenses remained stable at approximately $2.4 million for both the first quarters of 2025 and 2024. Compugen highlighted several operational updates, including the initiation of a platform trial for COM701 maintenance therapy in patients with platinum-sensitive ovarian cancer, and ongoing recruitment in a Phase 1 trial of GS-0321, a potential first-in-class anti-IL18BP antibody licensed to Gilead. Additionally, partner AstraZeneca has expanded their rilvegostomig program to ten Phase 3 trials across various cancers, with plans to present early data at the ASCO conference. The company maintains a solid financial position, with a cash runway expected to fund operations into 2027, and has announced key leadership transitions set to take effect in September 2025.